AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $282.56, with a market capitalization of 499.56B. The stock trades at a price-to-earnings (P/E) ratio of 80.70 and offers a dividend yield of 2.39%.
On 2026-10-19, AbbVie(ABBV) stock traded between a low of $282.56 and a high of $287.93. Shares are currently priced at $282.56, which is 0.0% above the low and -1.9% below the high.
AbbVie(ABBV) shares are trading with a volume of 3.99M, against a daily average of 5.9M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
ABBV News
...
AbbVie (ABBV) announced that its investigational ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin a4ss7, demonstrated higher rates of endoscopi...
AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (ABBV) announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology, UEG, Week, October...
AbbVie (NYSE:ABBV) reported extensive new inflammatory bowel disease data across major scientific meetings, spanning Crohn's disease and ulcerative colitis. Th...
Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest ra...
AbbVie (ABBV +0.71%), which accounts for 6.2% of my portfolio, is one of my favorite long-term dividend stocks. The pharmaceutical giant has raised its dividend...
Biopharma stocks like AbbVie and Eli Lilly are trading at or near all-time highs, in the latest signal that investors are seeking out the steady gains that come...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie’s latest early stage study tests a new oral drug, ABBV-1042, in healthy adults to tra...
AbbVie (ABBV Quick QuoteABBV - Free Report) and Sanofi (SNY Quick QuoteSNY - Free Report) are major pharmaceutical companies. AbbVie has a strong pr...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.